LEADER 01005cam2-2200337---450-
001 990005129870403321
005 20140407113010.0
010   $a3-458-32581-6
035   $a000512987
035   $aFED01000512987
035   $a(Aleph)000512987FED01
035   $a000512987
100   $a19990604d1985----km-y0itay50------ba
101 0 $ager
102   $aDE
105   $a--------001zy
200 1 $a<<1.: >>Stuttgarter Erzählungen$fWilhelm Raabe$ghrsg. von Hans-Jürgen Schrader
210   $aFrankfurt am Main$cInsel$d1985
215   $a341 p.$d18 cm
225 1 $aInsel taschenbuch$v881
461  0$1001000434337$aWilhelm Raabe Werke in Einzelausgaben$v01
676   $a838.8
700  1$aRaabe,$bWilhelm$f<1831-1910>$0132069
702  1$aSchrader,$bHans-Jürgen
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990005129870403321
952   $a833.8 RAABE 1(1;1)$bDip.f.m.5959/A$fFLFBC
959   $aFLFBC
996   $aStuttgarter Erzählungen$9534362
997   $aUNINA

LEADER 00798nam0-22003011i-450-
001 990000429230403321
005 20001010
035   $a000042923
035   $aFED01000042923
035   $a(Aleph)000042923FED01
035   $a000042923
100   $a20001010d--------km-y0itay50------ba
101 0 $aita
105   $ay-------001yy
200 1 $aGuida al calcestruzzo a vista$fMichael Gage
210   $aMilano$cGorlich$d1974
215   $a346 p.$cill.$d24 cm
300   $aSul verso del front. tit. orig.: Guide to exposed concrete finishes
610 0 $aCalcestruzzo
676   $a691
700  1$aGage,$bMichael
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990000429230403321
952   $a08 B 18$b6578$fDINED
959   $aDINED
997   $aUNINA
DB    $aING01

LEADER 02217nam  2200577   450 
001 9910827838803321
005 20230803021102.0
010   $a1-78084-270-8
010   $a1-78084-271-6
035   $a(CKB)2550000001101935
035   $a(EBL)1179645
035   $a(OCoLC)854971660
035   $a(SSID)ssj0001599928
035   $a(PQKBManifestationID)16306258
035   $a(PQKBTitleCode)TC0001599928
035   $a(PQKBWorkID)14892839
035   $a(PQKB)11287715
035   $a(MiAaPQ)EBC1179645
035   $a(Au-PeEL)EBL1179645
035   $a(EXLCZ)992550000001101935
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEmerging therapeutic options for hepatitis C /$feditors, Masao Omata, Tatsuo Kanda
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$d©2013
215   $a1 online resource (117 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-272-4 
327   $aTitle page; Copyright page; Contents; Foreword. Hepatitis C virus infection: from discovery to eradication; 1. Interferons in clinical trials; 2. Protease inhibitors; 3. NS5A inhibitor: daclatasvir; 4. Toll-like receptor agonists for nonresponders to hepatitis C virus treatment: hope versus promise?; 5. Treatment options in HIV-HCV-coinfected patients; 6. Treatment options for dual hepatitis C/hepatitis B virus coinfection; 7. Hepatitis C virus treatment in patients with metabolic syndrome; 8. Future directions in hepatitis C therapy; Index
330   $aEmerging Therapeutic Options for Hepatitis C
606   $aHepatitis C$xTreatment
606   $aHepatitis C$xChemotherapy
606   $aAntiviral agents
615  0$aHepatitis C$xTreatment.
615  0$aHepatitis C$xChemotherapy.
615  0$aAntiviral agents.
676   $a616.362306
702   $aOmata$b Masao
702   $aKanda$b Tatsuo
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910827838803321
996   $aEmerging therapeutic options for hepatitis C$94007384
997   $aUNINA